Curated News
By: NewsRamp Editorial Staff
October 14, 2026
Quantum BioPharma's Lucid-MS Clears FDA Hurdle for Phase 2 MS Trial
TLDR
- Quantum BioPharma gains an edge as FDA clears Lucid-MS for Phase 2 MS trials, potentially advancing a novel non-immune therapy.
- Lucid-MS inhibits PAD2 to protect nerve cells, and the Phase 2 trial will assess efficacy, safety, and brain imaging changes.
- Quantum BioPharma's Lucid-MS could improve MS treatment by protecting nerves, offering new hope for patients with multiple sclerosis.
- Quantum BioPharma's Lucid-MS aims to prevent myelin damage, a fresh approach for multiple sclerosis that just cleared FDA hurdles.
Impact - Why it Matters
This news matters because it represents a potential paradigm shift in treating multiple sclerosis. Current MS therapies primarily modulate the immune system, but Lucid-MS aims to protect nerve cells directly by inhibiting PAD2, an enzyme associated with myelin damage. If successful, this could offer a new treatment option for patients who do not respond adequately to existing therapies or who experience significant side effects. The FDA's clearance of the IND application is a critical step forward, allowing Quantum BioPharma to advance its lead compound into Phase 2 testing. Positive results could pave the way for a novel class of MS drugs, addressing an unmet need in a disease that affects millions worldwide. For investors, this milestone de-risks the program and highlights Quantum's innovative pipeline. Moreover, the company's other asset, UNBUZZD™, and its royalty agreement provide additional potential revenue streams, making Quantum a diversified player in the biopharma space.
Summary
Quantum BioPharma (NASDAQ: QNTM) has received U.S. Food and Drug Administration approval of its Investigational New Drug application for Lucid-MS, its multiple sclerosis candidate. This milestone clears the way for Phase 2 clinical testing of the drug, which is designed to protect nerve cells by inhibiting PAD2, an enzyme linked to myelin damage. Unlike many existing MS therapies that target the immune system, Lucid-MS offers a potentially different therapeutic approach. The planned Phase 2 study will be randomized, double-blind, and placebo-controlled, evaluating the drug’s efficacy, safety, and tolerability in MS patients. Researchers will assess clinical symptoms and changes visible through brain imaging. The compound previously completed Phase 1 trials in healthy volunteers, where it demonstrated a favorable safety profile and good tolerability.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Quantum also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.48% ownership stake as of June 30, 2026, and royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. This development was reported by BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Clears FDA Hurdle for Phase 2 MS Trial
